Fresenius is a health care group providing products and services for dialysis, hospitals and the medical care of patients at home. In addition, Fresenius focuses on hospital operation, as well as on engineering and services for hospitals and other health care facilities. About 122,000 employees have dedicated themselves to the service of health in about 100 countries worldwide.

 

FRESENIUS GROUP IN FIGURES
in million €	2008	2007	2006	2005	2004
Earnings
Sales	12,336	11,358	10,777	7,889	7,271
EBIT	1,7271)	1,609	1,444	969	845
Net income	4501)	410	330	222	168
Depreciation and amortization	783	421	399	320	315
Operating cash flow	1,074	1,296	1,052	780	851
Operating cash flow in % of sales	8.7%	11.4%	9.8%	9.9%	11.7%
Earnings per ordinary share in €	2.851)	2.64	2.158)	1.768)	1.368)
Earnings per preference share in €	2.861)	2.65	2.168)	1.778)	1.378)
Balance sheet
Total assets	20,544	15,324	15,024	11,594	8,188
Non-current assets	15,466	11,033	10,918	8,063	5,433
Equity2)	6,943	6,059	5,728	5,130	3,347
Equity ratio2)	34%	40%	38%	44%	41%
Investments 3)	4,617	1,318	4,314	2,247	421
Profitability
EBIT margin	14.0%1)	14.2%	13.4%	12.3%	11.6%
Return on equity after taxes (ROE) 4) 6) 9)	10.5%	12.0%	10.4%	11.4%	10.5%
Return on operating assets (ROOA) 4) 5) 9)	9.8%	11.4%	10.4%	11.7%	11.1%
Return on invested capital (ROIC) 4) 5) 9)	7.3%	8.4%	7.4%	8.0%	7.4%
Dividend per ordinary share in €	0.707)	0.66	0.57	0.498)	0.458)
Dividend per preference share in €	0.717)	0.67	0.58	0.508)	0.468)
Employees (December 31)	122,217	114,181	104,872	91,971	68,494

 

1)	Before special items from the APP acquisition
2)	Equity including minority interest
3)	Investments in property, plant and equipment and intangible assets, acquisitions
4)	2005: balance sheet adjusted for acquisition of HELIOS Kliniken
5)	2006 pro forma Renal Care Group, excluding earnings from the divestiture of US dialysis clinics as well as their first quarter 2006 earnings
6)	2006 pro forma Renal Care Group, excluding first quarter 2006 earnings of divested US dialysis clinics
7)	Proposal
8)	Adjusted for share split in February 2007
9)	2008 pro forma APP Pharmaceuticals and excluding special items from the acquisition
You will find a 10-year overview on our website: www.fresenius.com/Investor Relations.